Board Of Directors

Meet our Board.

Our board of directors is made up of healthcare leaders, innovative scientists, and more. They possess deep expertise in biopharmaceuticals, healthcare, commercial and operational leadership, finance, internal controls, senior management, internal medicine, HIV/AIDS, virology, and other disciplines. Board members meet regularly to maintain and accelerate the business’ trajectory in bringing our innovative biopharmaceutical therapeutics to the market. Here are their stories.

Board Of Directors Header Image

Frank Torti, MD

Dr. Torti has served as Chairperson of Arbutus’ board of directors since November 2018. Dr. Torti has served as the Vant Chair of Roivant Sciences, Inc. (RSI) since January 2020. In this capacity he serves as Chairperson of the boards of directors of the biopharmaceutical companies in the Roivant family and is responsible for the operations and management of those companies. He previously served as Vant Investment Chair of RSI, from August 2018 to December 2019. Prior to joining RSI, from August 2007 to August 2018, Dr. Torti served as a Partner of New Enterprise Associates (NEA), specializing in investments in healthcare. Prior to joining NEA, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics from 2002 to 2005 in various capacities, where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Dr. Torti presently serves as Chairperson of the board of directors of Immunovant, Inc., Sio Gene Therapies Inc. and several private biopharmaceutical companies. He has previously served on the boards of directors of numerous development and commercial stage public and private healthcare companies, including Myovant Sciences Ltd., Urovant Sciences Ltd., Annexon Biosciences, Inc., Eargo Inc., Galera Therapeutics, Inc., NeoTract, Inc., Novast Pharmaceuticals Ltd., OrphoMed, Inc., Tarveda Therapeutics, Inc. and XOC Pharmaceuticals, Inc. Dr. Torti earned an M.D. from the University of North Carolina School of Medicine, an M.B.A. from Harvard Business School and a B.A. from the University of North Carolina. Our board of directors believes that Dr. Torti’s extensive experience in healthcare investing, as well as his clinical trial background, qualifies him to serve on its board of directors.

William H. Collier
President and Chief Executive Officer

Mr. Collier joined Arbutus in June 2019 and serves as our President and Chief Executive Officer and is a member of the Board of Directors. Mr. Collier has more than 30 years of senior executive management, commercial and operational leadership experience in the pharmaceutical industry, predominantly with companies focused in anti-virals and vaccines. Prior to Arbutus, Mr. Collier served as President and General Manager, North America at ViiV Healthcare where he led the industry-leading launches of several new treatments for HIV. Prior to that, Mr. Collier held multiple senior leadership roles during his fifteen-year tenure at GlaxoSmithKline. Earlier in his career, he led the launches of new treatments for herpes and bacterial infections. Mr. Collier received his BSc in Mathematics and Management Sciences from the University of Manchester Institute of Science & Technology, UK, and served on The President’s Advisory Council on HIV/AIDS from 2014 to 2017.

Daniel Burgess
Independent Director

Mr. Burgess has served as a director of Arbutus’s board of directors since March 2017. He is currently a Venture Partner at SV Health Investors, is Chairman of the Board of Nabriva Therapeutics (Nasdaq: NBRV) and Cidara Therapeutics (Nasdaq: CDTX) as well as several private biotechnology companies. He is also Chief Executive Officer of Pulmocide Limited. Prior to his current roles, Mr. Burgess was President and CEO of Rempex Pharmaceuticals, a company he co-founded in 2011 and subsequently sold to The Medicines Company in December 2013. Prior to Rempex, Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, Inc., which was acquired by Aptalis Pharma Inc. in 2011. Previously, Mr. Burgess was Chief Operating Officer and Chief Financial Officer of Harbor BioSciences, Inc., formerly Hollis-Eden Pharmaceuticals, Inc. Prior to Hollis-Eden, Mr. Burgess spent ten years with Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Limited) where he held a variety of executive level positions with responsibility for overall finance for the company as well as a number of different operating units. Mr. Burgess holds a B.A. in economics from Stanford University and an M.B.A. from Harvard Business School. Based on his experience at Gensia Sicor and other organizations, Mr. Burgess provides the Board with critical perspectives on finance, accounting and internal controls issues.

Richard C. Henriques
Independent Director

Mr. Richard Henriques joined Arbutus’ board of directors in December 2014. Mr. Henriques is currently a Senior Fellow at the University of Pennsylvania with a focus on impact investing. He formerly served as Chief Financial Officer for the Bill & Melinda Gates Foundation with responsibility for finance and accounting, financial planning and analysis, strategic planning, measurement and evaluation, program related investments and information technology. Mr. Henriques’ background includes more than 25 years working at Merck & Co., Inc. during which time, he served as Senior Vice President of Finance for Global Human Health, Vice President and Corporate Controller, and Principal Accounting Officer, among other financial management roles. Mr. Henriques currently serves as a board member for EMulate Therapeutics, a privately held Seattle based bio-electronics company and Cabaletta Bio, a Philadelphia based publicly listed biotechnology company focused on B cell-mediated autoimmune diseases. He is also a member of the board of directors for The Franklin Institute, The Heritage Conservancy in Buck’s County Pennsylvania and Episcopal Community Services (a Philadelphia based social services organization). He holds a B.A. in Oriental Studies from the University of Pennsylvania and an M.B.A. with a concentration in Finance from The Wharton School.

Keith Manchester, MD
Independent Director

Dr. Manchester has served as a director since March 2015. Dr. Manchester is a partner and the Head of Life Sciences for QVT Financial LP, an investment firm, where he has been employed since 2005, and focuses on investments in both publicly traded and privately owned life sciences companies. Dr. Manchester also serves as a director of Kriya Therapeutics, Roivant Sciences Ltd. and Roivant Sciences, Inc. Prior to joining QVT, Dr. Manchester was Vice-President of Business Development from 2002 to 2004 and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, Inc., a biotechnology company. From 1999 to 2000, Dr. Manchester was an associate at Vestar Capital Partners, a private equity firm. From 1997 to 1999, Dr. Manchester was an investment banker in the healthcare group at Goldman, Sachs & Co. Dr. Manchester received his A.B. degree from Harvard College and his M.D. degree from Harvard Medical School.

James Meyers
Independent Director

Mr. Meyers joined the Arbutus board of directors in October 2018. He also serves as a Board Member for CytomX Therapeutics and Sangamo Therapeutics. In November 2020, Mr. Meyers became President and Chief Executive Officer of IntraBio Ltd., a privately-held biopharmaceutical company with a late-stage drug pipeline that includes treatment for genetic and neurodegenerative diseases. In addition, Mr. Meyers has served as a Senior Advisor to the Boston Consulting Group since January 2019, and has served as a Senior Advisor to Gilead Sciences, Inc. (“Gilead”) (Nasdaq: GILD) since his retirement from Gilead in February 2018. In his 22 years at Gilead, Mr. Meyers was one of a relatively small group of executives who were instrumental in transitioning the company from an innovative start-up to one of the most successful biopharmaceutical organizations in the world. Prior to his advisory role, Mr. Meyers served as Gilead’s Executive Vice President of Worldwide Commercial Operations, responsible for all commercial activities including pricing and market access. Mr. Meyers also led some of the most important and successful product launches in the history of the biopharmaceutical industry, most notably in the therapeutics areas of HCV and HIV. Prior to Gilead, Mr. Meyers served in roles of increasing responsibility at both Zeneca Pharmaceuticals and Astra U.S.A.. Mr. Meyers received his Bachelor’s degree in Economics from Boston College.

Melissa V. Rewolinski, PhD
Independent Director

Dr. Rewolinski joined the Arbutus board of directors in July 2023. Dr. Rewolinski currently serves as principal of MVR Consulting, where she specializes in providing counsel to small and mid-size biotechnology and pharmaceutical companies. Earlier she held a number of senior level R&D positions for Intercept, rising to Senior Vice President, Head of Technical Operations, and member of the Executive Team. Previously, she served as Senior Director, Development for Amira Pharmaceuticals, and before that as a Chemical Development Group Leader and a Pharmaceutical Sciences Project Team Leader for Pfizer Global R&D. Dr. Rewolinski began her career at Pharmacia & Upjohn as a post-doctoral research scientist. She currently serves as a board member for Lannett Company, Inc., and American Type Culture Collection (ATCC). Dr. Rewolinski earned a doctorate degree in organic chemistry and Bachelor of Science degree in chemistry, magna cum laude, from Rice University.



Learn about our organization’s strong leadership team.

Meet our Leadership Team

Meet Our Scientific Advisors

Scientific Advisors

Discover the scientists providing us their guidance and advisory.

Meet our Scientific Advisors